Kamada (KMDA)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $467.05M
Last updated: Nov 17, 2026 at 11:04 AM ET
Kamada (KMDA) Stock Forecast
Analysts expect Kamada (KMDA) to earn $0.50 per share in the fiscal year ending Dec 31, 2026, on revenue of $626.61M. Of 3 analysts, 3 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Dec 31, 2026 were revised up and 1 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 3 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 0 | 0.0% |
| Buy | 3 | 100.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 3
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 16.0% and revenue estimates rise 13.6%.
- Fiscal year ending Dec 31, 2026
- $0.50
- EPS consensus, revenue $626.61M
- Fiscal year ending Dec 31, 2027
- $0.58
- EPS consensus, revenue $712.00M
- Next report
- Mar 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.50 | $0.48 to $0.52 | 3 | $626.61M | $600.54M to $652.87M | 4 |
| Dec 31, 2027 | $0.58 | $0.46 to $0.72 | 3 | $712.00M | $677.12M to $731.95M | 3 |
Quarterly Estimates
The EPS consensus falls from $0.11 for the quarter ending Dec 31, 2026 to $0.10 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.11 | $0.09 to $0.14 | 6 | $52.09M | $45.22M to $57.09M | 6 |
| Mar 31, 2027 | $0.10 | $0.10 to $0.10 | 1 | $161.19M | $161.19M to $161.19M | 1 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 0 upward and 3 downward EPS revisions. Cuts outnumber raises in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 0 | 1 |
| Fiscal year ending Dec 31, 2027 | 0 | 1 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 16.3% from $0.43.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $0.50 | $0.48 | $0.48 | $0.49 | $0.43 | +17.0% |
| Fiscal year ending Dec 31, 2027 | $0.58 | $0.58 | $0.58 | $0.60 | $0.61 | -5.4% |
| Quarter ending Mar 31, 2027 | $0.10 | $0.10 | $0.10 | $0.11 | $0.11 | -9.1% |
Frequently Asked Questions About KMDA
What is the KMDA stock forecast?
Consensus analyst estimates put Kamada's EPS at $0.50 for the fiscal year ending Dec 31, 2026, on revenue of $626.61M. The consensus rating from 3 analysts is Buy.
How do analysts rate KMDA stock?
Of 3 analysts covering Kamada, 0 rate it Strong Buy, 3 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from KMDA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $0.50, with estimates from $0.48 to $0.52 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.58, with estimates from $0.46 to $0.72 from 3 analysts.
What revenue do analysts expect from Kamada next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $626.61M, with estimates from $600.54M to $652.87M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $712.00M, with estimates from $677.12M to $731.95M.
How many analysts cover KMDA?
3 analysts rate Kamada stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
KMDA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors